Indian court blocks Glenmark's cut-price Januvia, expedites patent case

India's Supreme Court has blocked any fresh manufacture by Glenmark of its cut-price version of Merck & Co's diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride).

India's Supreme Court has blocked any fresh manufacture by Glenmark of its cut-price version of Merck & Co's diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride).

The court has also, in what's probably an unprecedented move, made efforts to ensure that "highly contested commercial cases" such...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category